Chlamydia Trachomatis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Chlamydia Trachomatis Tests Market Report Overview
The Chlamydia Trachomatis Tests market size was valued at $634.7 million in 2022. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia Trachomatis. In women, Chlamydia Trachomatis infections are often asymptomatic, however, if left untreated they can cause pelvic inflammatory disease (PID), which in turn can lead to additional complications such as infertility, ectopic pregnancy, and chronic pelvic pain.
Chlamydia Trachomatis Tests Market Outlook 2022-2033 ($ Million)
For more insights on the Chlamydia Trachomatis Tests market forecast, download a free sample report
The Chlamydia Trachomatis Tests market research report is built to visualize quantitative market trends within in vitro diagnostics therapeutic areas. Furthermore, the model discusses in detail the impact of COVID-19 on the Chlamydia Trachomatis Tests market for the year 2020 and beyond.
Market Size (2022) | $634.7 million |
Historic Period | 2015-2022 |
Forecast Period | 2023-2033 |
Key Segments |
|
Key Regions |
|
Key Companies |
|
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Chlamydia Trachomatis Tests Market Dynamics
The Chlamydia trachomatis (CT) tests market is expected to increase during the forecast period, largely due to sales increases in the North American region. In Europe and Asia Pacific, growth is expected to occur in select countries, however, this is expected to be outweighed by declines in large CT testing markets such as France, UK, China and Japan.
The increasing prevalence of Chlamydia and opportunistic screening tests provided by healthcare facilities are the major drivers for CT testing in key North American and European markets. Factors that are expected to negatively impact the Chlamydia trachomatis tests market include changes to sexual and reproductive health service provision, switches in device usage, and declines in live birth rates.
For additional Chlamydia Trachomatis Tests market dynamics, download a free sample report
Chlamydia Trachomatis Tests Market Segments
The key segments in the Chlamydia Trachomatis Tests market are Chlamydia Trachomatis Nucleic Acid Amplification Tests (NAATs), Dual CT/NG Nucleic Acid Amplification Tests, and Other Chlamydia Trachomatis Tests. In 2022, the Dual CT/NG Nucleic Acid Amplification Tests segment dominated the market share.
The preferred method of screening for genital Chlamydia Trachomatis is via Nucleic Acid Amplification Tests (NAATs). This technique is used in laboratories across most of the countries and is generally considered superior to other tests such as the culture method. NAATs can be cost-effective while also providing optimum results due to the pooling of samples. Specimens screened using NAAT are not sent for confirmatory testing and the NAAT results are considered definitive.
Chlamydia Trachomatis Tests Market Analysis by Segments, 2022 (%)
To know more about the Chlamydia Trachomatis Tests market segments, download a free sample report
Chlamydia Trachomatis Tests Market Segmentation by Regions
The key regions in the Chlamydia Trachomatis Tests market are Asia-Pacific, Europe, the Middle East and Africa, North America, and South and Central America. In 2022, North America emerged as the leading regional segment with the US being the largest contributor to the regional market.
Growth of the United States CT tests markets is largely being driven by increases in the number of infection and suspected infection cases. Sales of CT tests is also bolstered by a high proportion of pregnant women undergoing CT screening. As such, increases in live birth rates are also expected to contribute to market growth.
Chlamydia Trachomatis Tests Market Analysis by Regions, 2022 (%)
For more regional insights in the Chlamydia Trachomatis Tests market, download a free sample report
Chlamydia Trachomatis Tests Market – Competitive Landscape
The key companies in the Chlamydia Trachomatis Tests market are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corp, Becton Dickinson and Co, Hologic Inc, ZeptoMetrix Corporation and Quidelortho Corp among others. In 2022, Hologic Inc accounted for the highest Chlamydia Trachomatis Tests market share and value.
Chlamydia Trachomatis Tests Market Analysis by Companies, 2022 (%)
For more company insights into the Chlamydia Trachomatis Tests market, download a free sample report
Segments Covered in this Report
Chlamydia Trachomatis Tests Segment Outlook ($ Million, 2015-2033)
- Chlamydia Trachomatis Nucleic Acid Amplification Tests (NAATs)
- Dual CT/NG Nucleic Acid Amplification Tests
- Other Chlamydia Trachomatis Tests
Chlamydia Trachomatis Tests Regional Outlook ($ Million, 2015-2033)
- Asia-Pacific
- Europe
- Middle East and Africa
- North America
- South and Central America
Key Inclusions of the market model are –
Currently marketed Chlamydia Trachomatis Tests market and evolving competitive landscape –
- Insightful review of the key industry trends.
- Annualized total Chlamydia Trachomatis Tests market revenue by segment and market outlooks from 2015-2033.
- Market-level data on units, average selling prices, and market values.
Global, Regional and Country level market specific insights –
- Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the Chlamydia Trachomatis Tests market.
- Competitive dynamics insights and trends provided for the Chlamydia Trachomatis Tests market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens AG, Diagnostica Stago SAS, Werfen Life Group SAU, Bio-Rad Laboratories Inc, bioMerieux SA, Quidel Corp, Danaher Corp, PerkinElmer Inc, and others.
Countries covered – United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
Scope
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for
- CMO executives who must have a deep understanding of the Chlamydia Trachomatis Tests marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
The model will enable you to –
- Understand the impact of COVID-19 on Chlamydia Trachomatis Tests.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving Chlamydia Trachomatis Tests.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Chlamydia Trachomatis Tests market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific Chlamydia Trachomatis Tests market from 2015-2033.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Abbott Laboratories
Thermo Fisher Scientific Inc
Danaher Corp
Becton Dickinson and Co
Hologic Inc
Quidel Corp
Bio-Rad Laboratories Inc
Trinity Biotech Plc
Frequently asked questions
-
What was the Chlamydia Trachomatis Tests market size in 2022?
The Chlamydia Trachomatis Tests market size was $634.7 million in 2022.
-
Which was the leading segment in the Chlamydia Trachomatis Tests market?
Dual CT/NG Nucleic Acid Amplification Tests segment was leading the Chlamydia Trachomatis Tests market in 2022.
-
Which region dominated the Chlamydia Trachomatis Tests market share?
North America held the largest share of the Chlamydia Trachomatis Tests market in 2022.
-
Which are the leading companies in the Chlamydia Trachomatis Tests market?
The key companies in the Chlamydia Trachomatis Tests market are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corp, Becton Dickinson and Co, Hologic Inc, ZeptoMetrix Corporation and Quidelortho Corp among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.